Orencia approved in third inflammatory disease

Bristol-Myers Squibb’s (NYSE: BMY) Orencia (abatacept) received US Food and Drug Administration (FDA) approval to treat adults with active psoriatic arthritis (PsA), the company announced on Thursday.

This approval, for both intravenous and subcutaneous injection formulations, marks the third autoimmune disease indication for the selective T-cell co-stimulation modulator.

Brian Gavin, Orencia development lead at the US pharma major, said: “This approval underscores the efficacy of Orencia in adult patients with active PsA, who have been in need of new treatments.”